This session will briefly review the incidence, etiology, anatomy and physiology of aortic stenosis and mitral regurgitation. It will describe percutaneous interventions of TAVR, MitraClip, and TMVR as well as future transcatheter therapies. Research trials and indications will be described to address the knowledge gap in practice.

Despite major advances in pharmacologic therapies for heart failure (HF) with impaired left ventricular function, HF is one of the leading causes for recurrent hospitalizations and mortality. HF is a chronic, progressive and ultimately debilitating disease with a high morbidity and in advanced stages with an annual mortality above 50%. This session will focus on management of pharmacologic and non-pharmacologic advanced heart failure. This session will introduce non-LVAD devices for the treatment of advanced heart failure.

The audience will be able to recognize Cardiogenic shock in their patients. They will be apprised of the categories and educated on the support available for these patients. They will see the need for using temporary support while final decisions on candidacy are made.

journey, and management strategies for your VAD patients.

LVADs are increasingly conceptualized as conventional therapies in end-stage organ dysfunction, however, this therapy carries significant risks, burdens and high mortality. Currently 5,000 to 6,000* patients are treated annually with LVADs; as a BTT, BTD or DT. At 1 year, approx. 10% patients have a stroke, 20% have a serious device-related infection, 30% have major bleeding, greater than 50% are re-hospitalized, and 20% die. Patients with LVADs are likely to develop complications requiring hospitalizations. Nurses need to understand why these patients are at risk for complications and how to manage them. This session will review potential complications of LVADs and how to minimize patient risk.

We will explore the current state of durable mechanical support focusing on novel technologies to maximize function of our current devices. We will then explore the next generation of technologies currently on the horizon.

The audience will understand the referral pattern for TAH. They will also learn the complications and risks that are involved. Visuals will be shown if available, as to how the TAH works.